One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates

One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates

Item

http://www.wikidata.org/entity/Q35140303

Q35140303

about

Human breast milk and antiretrovirals dramatically reduce oral HIV-1 transmission in BLT humanized mice CDC42 Use in Viral Cell Entry Processes by RNA Viruses Animal and human mucosal tissue models to study HIV biomedical interventions: can we predict success?Studies of retroviral infection in humanized mice Advances in HIV microbicide development New generation humanized mice for virus research: comparative aspects and future prospects Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice Targeted cytotoxic therapy kills persisting HIV infected cells during ART Efficient Inhibition of HIV Replication in the Gastrointestinal and Female Reproductive Tracts of Humanized BLT Mice by EFdA In vivo analysis of highly conserved Nef activities in HIV-1 replication and pathogenesis.Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.Controlling the HIV/AIDS epidemic: current status and global challenges Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies.Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis.HIV restriction by APOBEC3 in humanized mice.Superior human leukocyte reconstitution and susceptibility to vaginal HIV transmission in humanized NOD-scid IL-2Rγ(-/-) (NSG) BLT mice.Hypogammaglobulinemia in BLT humanized mice--an animal model of primary antibody deficiency.Generation of HIV latency in humanized BLT mice.MIV-150/zinc acetate gel inhibits cell-associated simian-human immunodeficiency virus reverse transcriptase infection in a macaque vaginal explant model.HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.In vivo analysis of Nef's role in HIV-1 replication, systemic T cell activation and CD4(+) T cell loss.Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.BLT humanized mice as a small animal model of HIV infection.Sublimable C5A delivery provides sustained and prolonged anti-HIV microbicidal activities.Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4+CD8+ thymocytes.Breast Milk of HIV-Positive Mothers Has Potent and Species-Specific In Vivo HIV-Inhibitory Activity.Role of Semen on Vaginal HIV-1 Transmission and Maraviroc Protection.Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines.Biology of mucosally transmitted sexual infection-translating the basic science into novel HIV intervention: a workshop summary.C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus Challenge.In vivo platforms for analysis of HIV persistence and eradication.Inefficient vaginal transmission of tenofovir-resistant HIV-1 ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions.CD19xCD3 DART protein mediates human B-cell depletion in vivo in humanized BLT mice APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model.A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice

P2860

Q21131400-50770DF1-1553-4EBE-AAB3-CF550B7F1B07 Q26774206-024A3888-6933-4C21-9B3C-DDD8EEEBC569 Q26777022-B862F12C-B94C-4E86-A7D3-51CCBC069EE0 Q26849806-6D5B5097-2056-4187-BFA7-64506014C7A5 Q26852858-9E930C26-409D-49EC-ACF9-E070F2AF8169 Q27014786-46D0EBFB-38BE-4D56-8332-886C1877B41E Q27318354-19EBB0E6-B9AE-4FC1-BC28-D7D1FEB83429 Q28488527-1D8A7D91-4BB0-4B35-ADB5-03B12A28428E Q28538598-6714A6FF-17C6-4F8F-B997-CAC684A6133E Q28552730-1563FFB7-B3A5-4C67-87F2-2EFC28763ECA Q30009533-DA9E7910-9DC8-49D8-A364-32D613915200 Q30412592-CE56E7D4-1679-4830-A721-E9D73822A148 Q30420558-35D35DAE-964B-4A39-A012-47CB9CF947E5 Q30447923-9A43FD16-F54A-4F31-B12A-7108A6EB2675 Q34474320-E5B0D0BB-BDDE-4241-9352-213AD8589436 Q34649651-239EE8CB-78DD-4D7A-8455-2B780CD3FED9 Q35154146-727F8501-5235-4410-A778-E3EB563D0031 Q35291397-18C326E4-C3F4-4A59-9A7E-240DADF2666F Q35666126-85F9052E-61FE-4C9B-9659-15E8A4A42101 Q35746218-9F32F475-BB66-4673-B835-A3488B70A57A Q35794988-49AD7124-3EB0-46B4-992C-FF9975035EF9 Q35848314-F586CD60-BA05-4A71-A394-09B87A7DCF4B Q35861437-73BE540B-A821-4741-917D-A95477086415 Q35973578-6F7BC505-758B-4239-8C93-7FE28ED1E6E3 Q35998374-EA05D184-52A6-4AAF-B49D-23FBFA39544F Q36018914-272482ED-378F-48FD-8671-3FDEF84AA514 Q36112824-D0B16F41-C289-44A7-954B-610FEB1A9E75 Q36208081-583B96D0-15D3-4F24-AE6A-43E22E80C0B3 Q36290832-8D5BDA6D-C584-4427-8733-D01211274B8D Q36308990-F7599EA2-5DF7-49C6-824B-DFC44B8B38CD Q36358993-D9203E39-F19A-4A95-9F12-CAC98669D422 Q36438963-A587BF9D-F232-40F9-9AF5-5E771633301D Q36515119-B14BF765-134E-4A76-AE80-B7962E0CCC95 Q36559597-07B2C5ED-50F9-4984-A593-4B72A518D9D6 Q36618563-F89DD1AC-6053-4BA8-8099-1E9E21AE30E9 Q36777155-67BD5E6A-DC2E-4CD3-8A73-BC33E3B98C52 Q36811931-4C9C0FCC-0C82-41EF-8F92-834724E7BC5B Q36840299-506E34DA-E64F-4FB4-9345-DDA8A8DE3FF2 Q36901505-B775B7A4-19B3-4B1D-B0A5-351E0CAAE2B0 Q36923075-B5130EC6-EC0F-4D29-AC1A-CEC9C84413D6

P2860

One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates

Item

http://www.wikidata.org/entity/Q35140303

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu